mProX™ Human HTR1D Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Due to the presence of HTR1D in human trigeminal ganglia, neurogenic inflammation and nociceptive activity within the trigeminovascular afferents may be HTR1D mediated. HTR1D undergoes a conformational change upon interaction with its ligand, 5-hydroxytryptamine, which initiates signaling via guanine nucleotide-binding proteins and controls the activity of downstream effectors. Adenylate cyclase activity could be inhibited by HTR1D signaling. Specifically through controlling the production of 5-hydroxytryptamine in the brain and consequently affecting neuronal activity, HTR1D operates on the central nervous system and influences movement and anxiety. HTR1D are involved in controlling the release of various neurotransmitters. HTR1D may be implicated in vasoconstriction, according to several investigations. Additionally, it serves as a receptor for several anxiolytic, antidepressant, and hallucinogenic medicines, as well as derivatives of the ergot alkaloid. The customized HTR1D stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.